Literature DB >> 15686466

GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.

Emily Carpenter1, Veronica Valverde-Garduno, Alex Sternberg, Chris Mitchell, Irene Roberts, Paresh Vyas, Ajay Vora.   

Abstract

Trisomy 21 [Down's syndrome (DS)] and mutations in transcription factor GATA1 predispose neonates to a transient myeloproliferative disorder (TMD) and/or acute megakaryocytic leukaemia (AMKL). The role of trisomy 21 in their pathogenesis is unclear. We previously reported two rare neonates without DS who had TMD, one of whom progressed to AMKL. Trisomy 21 was detected only in blood cells at presentation with TMD/AMKL and disappeared with disease resolution. We now show that the blood cells at presentation of TMD harboured GATA1 genomic DNA mutations, suggesting a requirement for trisomy 21 in haematopoietic cells, rather than other cell types, for development of TMD/AMKL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686466     DOI: 10.1111/j.1365-2141.2004.05342.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Transient abnormal myelopoiesis in a cytogenetically normal neonate.

Authors:  Kentaro Yanase; Keisuke Kato; Nobuko Katayama; Yoko Mouri; Chie Kobayashi; Junko Shiono; Masakazu Abe; Ai Yoshimi; Kazutoshi Koike; Jun-Ichi Arai; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2010-09-23       Impact factor: 2.490

2.  Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.

Authors:  Ming-Horng Tsai; Jia-Woei Hou; Chao-Ping Yang; Pong-Hong Yang; Shih-Ming Chu; Jen-Fu Hsu; Ming-Chou Chiang; Hsuan-Rong Huang
Journal:  Indian J Pediatr       Date:  2011-02-02       Impact factor: 1.967

3.  Trisomy 21 as the sole acquired karyotypic abnormality in biphenotypic acute leukemia.

Authors:  Satoko Oka; Taiji Yokote; Toshikazu Akioka; Satoshi Hara; Kichinosuke Kobayashi; Yuji Hirata; Nobuya Hiraoka; Motomu Tsuji; Toshiaki Hanafusa
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

4.  Hematopoietic disorders in Down syndrome.

Authors:  John K Choi
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 5.  Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.

Authors:  Rintaro Ono; Daisuke Hasegawa; Shinsuke Hirabayashi; Takahiro Kamiya; Kenichi Yoshida; Satoko Yonekawa; Chitose Ogawa; Ryota Hosoya; Tsutomu Toki; Kiminori Terui; Etsuro Ito; Atsushi Manabe
Journal:  Eur J Pediatr       Date:  2014-09-30       Impact factor: 3.183

Review 6.  Transient leukemia in a newborn without Down syndrome: case report and review of the literature.

Authors:  Laurence Rozen; Sophie Huybrechts; Laurence Dedeken; Catherine Heijmans; Barbara Dessars; Pierre Heimann; Frédéric Lambert; Denis F Noubouossie; Alina Ferster; Anne Demulder
Journal:  Eur J Pediatr       Date:  2013-11-20       Impact factor: 3.183

Review 7.  Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders.

Authors:  Satoshi Saida
Journal:  Curr Treat Options Oncol       Date:  2017-07

8.  Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.

Authors:  Henrik Hasle; Ronald M Kline; Eigil Kjeldsen; Nik F Nik-Abdul-Rashid; Deepa Bhojwani; Jeffrey M Verboon; Stephanie P DiTroia; Katherine R Chao; Klas Raaschou-Jensen; Josefine Palle; C Michel Zwaan; Charlotte Guldborg Nyvold; Vijay G Sankaran; Alan B Cantor
Journal:  Blood       Date:  2022-05-26       Impact factor: 25.476

Review 9.  Haematology of Down syndrome.

Authors:  David Webb; Irene Roberts; Paresh Vyas
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09-05       Impact factor: 5.747

10.  Hyperleukocytosis in a neonate: A diagnostic dilemma.

Authors:  K Shreedhara Avabratha; Kiran Joseph Tauro; G K Shwethadri
Journal:  Indian J Med Paediatr Oncol       Date:  2010-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.